Withanolide B

Modify Date: 2024-01-11 16:59:40

Withanolide B Structure
Withanolide B structure
Common Name Withanolide B
CAS Number 56973-41-2 Molecular Weight 454.59800
Density 1.206 Boiling Point N/A
Molecular Formula C28H38O5 Melting Point N/A
MSDS Chinese USA Flash Point N/A

 Use of Withanolide B


Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].

 Names

Name Lycium substance B
Synonym More Synonyms

 Withanolide B Biological Activity

Description Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].
Related Catalog
In Vitro Withanolide B (1-100 nM; 3-5 days) significantly increases the expression of COL1A1 and RUNX2 genes and proteins in hBMSCs[1]. Withanolide B (1-100 nM; 11 or 3 days) increases the formation of extracellular matrix calcium deposits and increased the activity of alkaline phosphatase (ALP)[1]. Withanolide B (1-100 nM; 3-5 days) increases the protein expressions of p-ERK and active β-catenin of hBMSCs[1]. Withanolide B (10-100 μM; 48 h) reverses the Aβ42 aggregation-induced toxicy in SK-N-SH cells[2]. Cell Viability Assay[1] Cell Line: Human bone mesenchymal stem cells Concentration: 1, 10, 100 nM Incubation Time: 3, 5 days Result: Significantly increased the expression of COL1A1 and RUNX2.
In Vivo Withanolide B (10 mg/kg; topical administration) promotes bone healing in a rat tibial defect model[1]. Animal Model: Male Sprague-Dawley rats (8 weeks, 200 g) with tibial defect[1] Dosage: 10 mg/kg Administration: Injected in situ at the bone defect site at different time points (0, 3, 5, 7, and 9 days) Result: Increased the trabecular number, trabecular thickness and the thickness of the cortical bone.
References

[1]. Kuang Z, et, al. Withanolide B promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERK1/2 and Wnt/β-catenin signaling pathways. Int Immunopharmacol. 2020 Nov;88:106960.

[2]. Dubey S, et, al. Improving the inhibition of β-amyloid aggregation by withanolide and withanoside derivatives. Int J Biol Macromol. 2021 Mar 15;173:56-65.

[3]. Sivanandha G, et, al. Enhanced biosynthesis of withanolides by elicitation and precursor feeding in cell suspension culture of Withania somnifera (L.) Dunal in shake-flask culture and bioreactor. PLoS One. 2014 Aug 4;9(8):e104005.

 Chemical & Physical Properties

Density 1.206
Molecular Formula C28H38O5
Molecular Weight 454.59800
Exact Mass 454.27200
PSA 76.13000
LogP 4.38050

 Safety Information

Hazard Statements H413
RIDADR NONH for all modes of transport

 Synonyms

UNII-9YU877VU8K
Withanolide B